Slingshot members are tracking this event:

Merck's (MRK) Marketing Authorization Application (MAA) for Avelumab in Rare Skin Cancer Validated by European Medicines Agency (EMA)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 31, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Avelumab, Marketing Authorization Application, Maa, Rare Skin Cancer, European Medicines Agency